| [1] |
Jeon J, Du M, Schoen RE, et al. Determining Risk of Colorectal Cancer and Starting Age of Screening Based on Life style, Environmental, and Genetic Factors [J]. Gastroenterology, 2018, S0016-5085 (18): 30224-30225.
|
| [2] |
Qiu T, Chen W, Li P, et al. Subsequent anti-VEGF therapy after first-line anti-EGFRtherapy improved overall survival of patients with metastaticcolorectal cancer [J]. Onco Targets Ther, 2018, 11: 465-471.
|
| [3] |
Viale G, Trapani D, Curigliano G. Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy [J]. Biomed Res Int, 2017, 2017: 4719194.
|
| [4] |
Dekker E, Rex DK. Advances in CRC prevention: screening and surveillance [J]. Gastroenterology, 2018, S0016-5085 (18): 30219-30211.
|
| [5] |
Khakoo S, Georgiou A, Gerlinger M, et al. Circulating tumour DNA, a promising biomarker for the management of colorectal cancer [J]. Crit Rev Oncol Hematol, 2018, 122 :72-82.
|
| [6] |
Allen JE, Sharma P. Polyp characterization at colonoscopy: Clinical implications [J]. Best Pract Res Clin Gastroenterol, 2017, 31(4): 435-440.
|
| [7] |
Angarita FA, Feinberg AE, Feinberg SM. Management of complex polyps of the colon and rectum [J]. Int J Colorectal Dis, 2018, 33(2):115-129.
|
| [8] |
Li K, Tian H. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy [J]. J Drug Target, 2018:1-13.
|
| [9] |
Jean F, Tomasini P, Barlesi F. Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A reviewof efficacy, safety and place in therapy [J]. Ther Adv Med Oncol, 2017, 9(12): 769-779.
|
| [10] |
Lemery S, Keegan P, Pazdur R. First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication [J]. N Engl J Med, 2017, 377(15):1409-1412.
|
| [11] |
Atkins MB, Plimack ER, Puzanov I, et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial [J]. Lancet Oncol, 2018, 19(3): 405-415.
|
| [12] |
Overman MJ, Lonardi S, Wong KYM, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer [J]. J Clin Oncol, 2018, 10; 36(8): 773-779.
|
| [13] |
Kohei Shitara, Kentaro Yamazaki, Hiroyuki Uetake. et al. Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE) [J]. J Clin Oncol, 2014, 32:15 suppl, TPS3662-TPS3662.
|
| [14] |
Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line [J]. J Clin Oncol, 2005, 23(36): 9441-9442.
|
| [15] |
Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial [J]. Lancet Oncol, 2014, 15(10): 1065-1075.
|
| [16] |
Stintzing S, Modest DP, Rossius L, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial [J]. Lancet Oncol, 2016, 17(10): 1426-1434.
|
| [17] |
Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial [J]. JAMA, 2017, 317(23): 2392-2401.
|
| [18] |
Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumor side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials [J]. Ann Oncol, 2017, 28(8):1713-1729.
|
| [19] |
Qiu T, Chen W, Li P, et al. Subsequent anti-VEGF therapy after first-line anti-EGFR therapy improved overall survival of patients with metastatic colorectal cancer [J]. Onco Targets Ther, 2018, 11:465-471.
|
| [20] |
J. Bennouna S, Hiret C, Borg A, et al. Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18) [J]. Ann Oncol, 2017, 28, suppl_5, abs 4770.
|
| [21] |
Hecht JR, Cohn A, Dakhil S, et al. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer [J]. Clin Colorectal Cancer, 2015, 14(2): 72-80.
|
| [22] |
Cascinu S, Rosati G, Nasti G, et al. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients [J]. Eur J Cancer, 2017, 83:106-115.
|